Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 42, Issue , 2013, Pages 101-114

  Anderson, George ^a   Maes, Michael ^b   Berk, Michael ^c,d,e,f  

^a CRC   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cytokines; Depression; Inflammation; Oxidative stress; Schizophrenia; Tryptophan

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; KYNURENINE; MANGANESE SUPEROXIDE DISMUTASE; MELATONIN; MESSENGER RNA; MINOCYCLINE; MU OPIATE RECEPTOR; MYELOPEROXIDASE; NEUROLEPTIC AGENT; NEURONAL NITRIC OXIDE SYNTHASE; PLACEBO; QUINOLINIC ACID; REACTIVE OXYGEN METABOLITE; SECRETORY PHOSPHOLIPASE A2; TRANSFORMING GROWTH FACTOR BETA1; TRYPTOPHAN; TRYPTOPHAN CATABOLITE; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; AMINO ACID METABOLISM; ARTICLE; AUTOIMMUNITY; BIPOLAR DISORDER; CELLULAR IMMUNITY; COGNITIVE DEFECT; COMORBIDITY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DEPRESSION; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; INTRAUTERINE INFECTION; LIPID PEROXIDATION; MAJOR DEPRESSION; MITOCHONDRIAL RESPIRATION; MOLECULAR PATHOLOGY; NEGATIVE SYNDROME; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION;

ANIMALS; COMORBIDITY; DEPRESSIVE DISORDER; HUMANS; INFLAMMATION; NITROSATION; OXIDATIVE STRESS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 84873526680     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.07.016     Document Type: Article

References (263)

1. Adell A., Jiménez-Sánchez L., López-Gil X., Romón T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia?. Schizophr Bull 2012, 38(1):9-14.
2. Akiibinu M.O., Ogundahunsi O.A., Ogunyemi E.O. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Note 2012, 5(1):169.
3. an der Heiden W., Könnecke R., Maurer K., Ropeter D., Häfner H. Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005, 255(3):174-184.
4. Anderson G. Prenatal corticosteroids: pretermer outcomes, stress, schizophrenia, multiple sclerosis and the developmental role of melatonin and vitamin D3. J Pediatr Adolesc Gynecol 2010, 23(5):317-320.
5. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011, 76:54-60.
6. Anderson G., Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 2012, 27(2):113-119.
7. Anderson G., Maes M. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry 2012, [[Epub ahead of print] PubMed PMID: 22800757].
8. Anderson G., Maes M., Berk M. Biological underpinnings of the commonalities in depression, somatization, and chronic Fatigue Syndrome. Med Hypotheses 2012, 78:752-756.
9. Arakawa S., Shirayama Y., Fujita Y., Ishima T., Horio M., Muneoka K., et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 2012, 100(3):601-606.
10. Arora A., Avasthi A., Kulhara P. Subsyndromes of chronic schizophrenia: a phenomenological study. Acta Psychiatr Scand 1997, 96(3):225-229.
11. Arvindakshan M., Ghate M., Ranjekar P.K., Evans D.R., Mahadik S.P. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003, 62(3):195-204.
12. Avgustin B., Wraber B., Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 2005, 46(2):268-274.
13. Banerjee J., Alkondon M., Pereira E.F., Albuquerque E.X. Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid. J Pharmacol Exp Ther 2012, 341(2):500-509. [May].
14. Benros M.E., Nielsen P.R., Nordentoft M., Eaton W.W., Dalton S.O., Mortensen P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011, 168(12):1303-1310.
15. Bentsen H., Solberg D.K., Refsum H., Gran J.M., Bøhmer T., Torjesen P.A., et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry 2011, 70(1):97-105.
16. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009, 12(4):441-445.
17. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007, 100(1-3):279-281.
18. Berk M., Sanders K.M., Pasco J.A., Jacka F.N., Williams L.J., Hayles A.L., et al. Vitamin D deficiency may play a role in depression. Med Hypotheses 2007, 69(6):1316-1319.
19. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64(6):468-475.
20. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008, 29(7):346-351.
21. Bernstein H.G., Steiner J., Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009, 9:1059-1071.
22. Beurel E., Yeh W.-I., Michalek S.M., Harrington L.E., Jope R.S. Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells. J Immunol 2011, 186:1391-1398.
23. Bilici M., Efe H., Körogglu M.A., Uydu H.A., Bekarogglu M., Degger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64(1):43-51.
24. Birchwood M., Mason R., MacMillan F., Healy J. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993, 23(2):387-395.
25. Birchwood M., Iqbal Z., Chadwick P., Trower P. Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression. Br J Psychiatry 2000, 177:516-521.
26. Bonnin A., Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience 2011, 197:1-7.
27. Bošković M., Vovk T. Kores Plesničar B. Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9(2):301-312. [Jun].
28. Bright J.J., Sriram S. TGF-beta inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J Immunol 1998, 161(4):1772-1777.
29. Brown A.S. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011, 93:23-58.
30. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-280.
31. Brown A.S., Patterson P.H. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull 2011, 37:284-290.
32. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Mediators Inflamm 1993, 2(1):3-21.
33. Catts V.S., Catts S.V., Jablensky A., Chandler D., Weickert C.S., Lavin M.F. Evidence of aberrant DNA damage response signalling but normal rates of DNA repair in dividing lymphoblasts from patients with schizophrenia. World J Biol Psychiatry 2012, 13(2):114-125.
34. Chakrabarti S., Chang A., Gintzler A.R. Subcellular localization of mu-opioid receptor G(s) signaling. J Pharmacol Exp Ther 2010, 333(1):193-200.
35. Che Y., Wang J.F., Shao L., Young T. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010, 35(5):296-302.
36. Chen Y., Guillemin G.J. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009, 2:1-19.
37. Chen F., Lawrence A.J. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G proteins in the amygdala of fawn-hooded rats. J Pharmacol Exp Ther 2004, 310:1020-1026.
38. Chen C., Tan B., Zhou Y., Zhou J., He Y., Li S., et al. IL-28B genetic variant is associated with the risk of schizophrenia in the Chinese Han population. DNA Cell Biol 2012, 31(6):988-992. [Jun].
39. Chen S.J., Chao Y.L., Chen C.Y., Chang C.M., Wu E.C., Wu C.S., et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. Br J Psychiatry 2012, 200(5):374-380. [May].
40. Chong R.Y., Oswald L., Yang X., Uhart M., Lin P.I., Wand G.S. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2006, 31(1):204-211.
41. Condray R., Dougherty G.G., Keshavan M.S., Reddy R.D., Haas G.L., Montrose D.M., et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011, 14:756-767.
42. Connor M. Shadows across mu-star? Constitutively active mu-opioid receptors revisited. Br J Pharmacol 2009, 156(7):1041-1043.
43. Creed T.J., Lee R.W., Newcomb P.V., di Mambro A.J., Raju M., Dayan C.M. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol 2009, 183(1):164-171.
44. Cui H., Nishiguchi N., Yanagi M., Fukutake M., Mouri K., Kitamura N., et al. A putative cis-acting polymorphism in the NOS1 gene is associated with schizophrenia and NOS1 immunoreactivity in the postmortem brain. Schizophr Res 2010, 121:172-178.
45. Cui X., Pelekanos M., Burne T.H., McGrath J.J., Eyles D.W. Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. Neurosci Lett 2010, 486(3):220-223.
46. Curley A.A., Lewis D.A. Cortical basket cell dysfunction in schizophrenia. J Physiol 2012, 590(Pt 4):715-724.
47. Dakhale G.N., Khanzode S.D., Khanzode S.S., Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005, 182(184):494-498.
48. Dean O.M., Data-Franco J., Giorlando F., Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012, 26(5):391-401.
49. Do K.Q., Trabesinger A.H., Kirsten-Krüger M., Lauer C.J., Dydak U., Hell D. Schizophrenia: glutathione deficit in cerebrospinal fluid and pre-frontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728.
50. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
51. Drexhage R.C., Hoogenboezem T.A., Cohen D., Versnel M.A., Nolen W.A., van Beveren N.J., et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 2011, 24:1-10.
52. Fallin M.D., Lasseter V.K., Avramopoulos D., Nicodemus K.K., Wolyniec P.S., McGrath J.A., et al. Bipolar I disorder and schizophreni: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005, 77:918-936.
53. Fatemi S.H., Araghi-Niknam M., Laurence J.A., Stary J.M., Sidwell R.W., Lee S. Glial fibrillary acidic protein and glutamic acid decarboxylase 65 and 67kDa proteins are increased in brains of neonatal BALB/c mice following viral infection in utero. Schizophr Res 2004, 69:121-123.
54. Forlenza M.J., Miller G.E. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom Med 2006, 68(1):1-7.
55. Franchi S., Moretti S., Castelli M., Lattuada D., Scavullo C., Panerai A.E., et al. Mu opioid receptor activation modulates toll like receptor 4 in murine macrophages. Brain Behav Immun 2012, 26:480-488.
56. Franklin M., Bermudez I., Murck H., Singewald N., Gaburro S. Sub-chronic dietary tryptophan depletion-an animal model of depression with improved face and good construct validity. J Psychiatr Res 2012, 46(2):239-247.
57. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., Alonso C.M., et al. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry 2010, 51(8):935-943.
58. Galecka E., Szemraj J., Florkowski A., Galecki P., Biekiewicz M., Karbownik-Lewinska M., et al. Single nucleotide polymorphisms and mRNA expression for melatonin MT(2) receptor in depression. Psychiatry Res 2011, 189(3):472-474.
59. Galecki P., Szemraj J., Biekiewicz M., Florkowski A., Galecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009, 61(3):436-447.
60. Galecki P., Smigielski J., Florkowski A., Bobinska K., Pietras T., Szemraj J. Analysis of two polymorphisms of the manganese superoxide dismutase gene: Ile-58Thr and Ala-9Val in patients with recurrent depressive disorder. Psychiatry Res 2010, 179(1):43-46.
61. Galecki P., Szemraj J., Bartosz G., Biekiewicz M., Galecka E., Florkowski A., et al. Single-nucleotide polymorphisms and mRNA expression for melatonin synthesis rate-limiting enzyme in recurrent depressive disorder. J Pineal Res 2010, 48(4):311-317.
62. Galecki P., Maes M., Florkowski A., Lewiski A., Galecka E., Biekiewicz M., et al. Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 2011, 129(1-3):175-182.
63. Galecki P., Galecka E., Maes M., Chamielec M., Orzechowska A., Bobinska K., et al. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 2012, 138(3):360-366.
64. Ganzinelli S., Borda E., Sterin-Borda L. Autoantibodies from schizophrenia patients induce cerebral cox-1/iNOS mRNA expression with NO/PGE2/MMP-3 production. Int J Neuropsychopharmacol 2010, 13(3):293-303.
65. Garriock H.A., Tanowitz M., Kraft J.B., Dang V.C., Peters E.J., Jenkins G.D., et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010, 167(5):565-573.
66. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14(1):123-130.
67. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Yatham L.N., Young L.T. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 2011, 14(8):1069-1074.
68. Gee D.G., Karlsgodt K.H., van Erp T.G., Bearden C.E., Lieberman M.D., Belger A., et al. Altered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study. Schizophr Res 2012, 134(1):1-9.
69. Gorwood P., Corruble E., Falissard B., Goodwin G.M. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008, 165:731-739.
70. Goshen I., Kreisel T., Ben-Menachem-Zidon O., Licht T., Weidenfeld J., Ben-Hur T., et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008, 13(7):717-728.
71. Gozdzik-Zelazny A., Borecki L., Pokorski M. Depressive symptoms in schizophrenic patients. Eur J Med Res 2011, 16(12):549-552.
72. Gris P., Cheng P., Pierson J., Maixner W., Diatchenko L. Molecular assays for characterization of alternatively spliced isoforms of the u opioid receptor (MOR). Methods Mol Biol 2010, 617:421-435.
73. Harrow M., Yonan C.A., Sands J.R., Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?. Schizophr Bull 1994, 20(2):327-338.
74. Harvey B.H., Joubert C., du Preez J.L., Berk M. Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res 2008, 33(3):508-517.
75. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61(2):105-123.
76. Hashimoto M., Sagara Y., Langford D., Everall I.P., Mallory M., Everson A., et al. Fibrobals growth factor 1 regulates signalling via glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 2002, 277(36):32985-32991.
77. Heckers S. Diagnostic criteria for schizoaffective disorder. Expert Rev Neurother 2012, 12(1):1-3.
78. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38(2):247-252.
79. Herva A., Laitinen J., Miettunen J., Veijola J., Karvonen J.T., Läksy K., et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes (Lond) 2006, 30(3):520-527. [Mar].
80. Himmerich H., Milenovi S., Fulda S., Plümäkers B., Sheldrick A.J., Michel T.M., et al. Regulatory T cells increased while IL-1 decreased during antidepressant therapy. J Psychiatr Res 2010, 44(15):1052-1057.
81. Hinwood M., Morandini J., Day T.A., Walker F.R. Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex 2012, 22(6):1442-1454. [Jun].
82. Hoang M.T., Defina L.F., Willis B.L., Leonard D.S., Weiner M.F., Brown E.S. Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. Mayo Clin Proc 2011, 86(11):1050-1055.
83. Hutchinson M.R., Northcutt A.L., Chao L.W., Kearney J.J., Zhang Y., Berkelhammer D.L., et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 2008, 22(8):1248-1256.
84. Imagawa M. Low erythrocyte coenzyme Q10 level in schizophrenic patients. Jpn J Psychiatry Neurol 1989, 43(2):143-145.
85. Jacka FN, Maes M, Pasco JA, Williams LJ, Berk M. Nutrient intakes and the common mental disorders in women. J Affect Disord in press.
86. Janelidze S., Mattei D., Westrin Å., Träskman-Bendz L., Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011, 25(2):335-339.
87. Jin C.Y., Lee J.D., Park C., Choi Y.H., Kim G.Y. Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacol Sin 2007, 28(10):1645-1651.
88. Johnson D.A.W. Studies of depressive symptoms in schizophrenia I. The prevalence of depression and its possible causes. Br J Psychiatry 1981, 139:81-101.
89. Juckel G., Manitz M.P., Brüne M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammational animal model of schizophrenia a pilot study. Schizophr Res 2011, 131:96-100.
90. Karrenbauer B.D., Müller C.P., Ho Y.J., Spanagel R., Huston J.P., Schwarting R.K., et al. Time-dependent in-vivo effects of interleukin-2 on neurotransmitters in various cortices: relationships with depressive-related and anxiety-like behaviour. J Neuroimmunol 2011, 237(1-2):23-32.
91. Kekesi O., Tuboly G., Szucs M., Birkas E., Morvay Z., Benedek G., et al. Long-lasting, distinct changes in central opioid receptor and urinary bladder functions in models of schizophrenia in rats. Eur J Pharmacol 2011, 661(1-3):35-41.
92. Kennedy S.E., Koeppe R.A., Young E.A., Zubieta J.K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006, 63(11):1199-1208.
93. Kessing L.V., Andersen P.K. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?. J Neurol Neurosurg Psychiatry 2004, 75:1662-1666.
94. Khandaker G.M., Dibben C.R., Jones P.B. Does maternal body mass index during pregnancy influence risk of schizophrenia in the adult offspring?. Obes Rev 2012, 13(6):518-527.
95. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003, 8(6):365-370.
96. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H., et al. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002, 7(10):1107-1114.
97. Kim Y.K., Paik J.W., Lee S.W., Yoon D., Han C., Lee B.H. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(6):1091-1096.
98. Kim Y.K., Na K.S., Shin K.H., Jung H.Y., Choi S.H., Kim J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(5):1044-1053.
99. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
100. Kodydkova J., Vávrová L., Zeman M., Jirák R., Macásek J., Stanková B., et al. Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009, 42(13-14):1368-1374.
101. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 2008, 105(2):751-756.
102. Korgaonkar M.S., Grieve S.M., Koslow S.H., Gabrieli J.D., Gordon E., Williams L.M. Loss of white matter integrity in major depressive disorder: evidence using tract-based spatial statistical analysis of diffusion tensor imaging. Hum Brain Mapp 2011, 32(12):2161-2171.
103. Kraus J. Regulation of mu-opioid receptors by cytokines. Front Biosci (Schol Ed) 2009, 1:164-170.
104. Kraus J., Börner C., Lendeckel U., Höllt V. Interferon-gamma down-regulates transcription of the mu-opioid receptor gene in neuronal and immune cells. J Neuroimmunol 2006, 181(1-2):13-18.
105. Kristo C., Godang K., Ueland T., Lien E., Aukrust P., Froland S.S., et al. Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. Eur J Endocrinol 2002, 146(3):389-395.
106. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 2005, 17(2):227-231.
107. Kubera M., Obuchowicz E., Goehler L., Brzeszcz J., Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):744-759.
108. Kucinski A., Syposs C., Wersinger S., Bencherif M., Stachowiak M.K., Stachowiak E.K. α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia. Schizophr Res 2012, 136(1-3):82-87. [Apr].
109. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(7):1677-1681.
110. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010, 71(5):520-527.
111. Langsdorf E.F., Mao X., Chang S.L. A role for reactive oxygen species in endotoxin-induced elevation of MOR expression in the nervous and immune systems. J Neuroimmunol 2011, 236(1-2):57-64.
112. Lanoix D, Guérin P, Vaillancourt C. Placental melatonin production and melatonin receptor expression are altered in preeclampsia: new insights into the role of this hormone in pregnancy. J Pineal Res in press. doi:10.1111/j.1600-079X.2012.01012.x.
113. Lapin I.P. Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv Exp Med Biol 2003, 527:121-125.
114. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 2010, 210(1):84-91.
115. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav 2011, 98:161-168.
116. Lee K.M., Kim Y.K. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006, 6(8):1298-1304.
117. Lee M., Jayathilake K., Dai J., Meltzer H.Y. Decreased plasma tryptophan and tryptophan/large neutral amino acid ratio in patients with neuroleptic-resistant schizophrenia: relationship to plasma cortisol concentration. Psychiatry Res 2011, 185(3):328-333.
118. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2):764-785.
119. Levitt E.S., Clark M.J., Jenkins P.M., Martens J.R., Traynor J.R. Differential effect of membrane cholesterol removal on mu- and delta-opioid receptors: a parallel comparison of acute and chronic signaling to adenylyl cyclase. J Biol Chem 2009, 284(33):22108-22122.
120. Levitt E.S., Purington L.C., Traynor J.R. Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol 2011, 79(3):461-471.
121. Levkovitz Y., Mendlovich S., Riwkes S., Braw Y., Levkovitch-Verbin H., Gal G., et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138-149.
122. Liebau C., Baltzer A.W., Schmidt S., Roesel C., Karreman C., Prisack J.B., et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002, 22(2A):931-936.
123. Liu Y., Ho R.C., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012, 139(3):230-239. [Aug].
124. Liu Y.F., Quirion R. Modulatory role of glutathione on mu-opioid, substance P/neurokinin-1, and kainic acid receptor binding sites. J Neurochem 1992, 59(3):1024-1032.
125. Liu J., Liu J., Zhou Y., Li S., Li Y., Song X., et al. Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol 2011, 30(11):913-917.
126. Lobato K.R., Cardoso C.C., Binfaré R.W., Budni J., Wagner C.L., Brocardo P.S., et al. alpha-Tocopherol administration produces an antidepressant-like effect in predictive animal models of depression. Behav Brain Res 2010, 209(2):249-259.
127. Luchowska E., Kloc R., Olajossy B., Wnuk S., Wielosz M., Owe- Larsson B., et al. beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(3):519-529.
128. Machon R.A., Mednick S.A., Huttunen M.O. Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1997, 54(4):322-328.
129. Maes M. A review on the acute phase response in major depression. Rev Neurosci 1993, 4(4):407-416.
130. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008, 29(3):287-291.
131. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):664-675.
132. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis 2012, [[Epub ahead of print] PubMed PMID: 22773310].
133. Maes M., Meltzer H.Y. The serotonin hypothesis of major depression. Selected chapters on mood disorders. Psychopharmacology, The fourth generation of progress 1995, 933-944. Raven Press, New York. F. Bloom, D. Kupfer (Eds.).
134. Maes M., Bosmans E., Suy E., Vandervorst C., De Jonckheere C., Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology 1990, 24(3):115-120.
135. Maes M., Bosmans E., Suy E., Vandervorst C., DeJonckheere C., Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991, 84(4):379-386.
136. Maes M., Lambrechts J., Bosmans E., Jacobs J., Suy E., Vandervorst C., et al. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992, 22(1):45-53.
137. Maes M., Meltzer H.Y., Scharpé S., Bosmans E., Suy E., De Meester I., et al. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993, 49(2):151-165.
138. Maes M., Scharpé S., Meltzer H.Y., Okayli G., Bosmans E., D'Hondt P., et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994, 54(2):143-160.
139. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1995, 244(246):325-329.
140. Maes M., Vandoolaeghe E., Ranjan R., Bosmans E., Van Gastel A., Bergmans R., et al. Increased serum soluble CD8 or suppressor/cytotoxic antigen concentrations in depression: suppressive effects of glucocorticoids. Biol Psychiatry 1996, 40(12):1273-1281.
141. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996, 21(1):39-50.
142. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997, 26(2-3):221-225.
143. Maes M., Vandoolaeghe E., Neels H., Demedts P., Wauters A., Meltzer H.Y., et al. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 1997, 42(5):349-358.
144. Maes M., Van Bockstaele D.R., Gastel A., Song C., Schotte C., Neels H., et al. The effects of psychological stress on leukocyte subset distribution in humans: evidence of immune activation. Neuropsychobiology 1999, 39(1):1-9.
145. Maes M., De Vos N., Pioli R., Demedts P., Wauters A., Neels H., et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000, 58(3):241-246.
146. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Lower plasma coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 2009, 30:462-469.
147. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/fatigue syndrome. Neuro Endocrinol Lett 2009, 30(6):715-722.
148. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010, 125(1-3):287-294.
149. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):676-692.
150. Maes M., Kubera M., Obuchowiczwa E., Goehler L., Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011, 32(1):7-24.
151. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):702-721.
152. Maes M., Mihaylova I., Kubera M., Leunis J.C., Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2011, 135(1-3):414-418.
153. Maes M., Berk M., Goehler L., Song C., Anderson G., Gałlecki P., et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012, 10:66.
154. Maes M., Ringel K., Kubera M., Berk M., Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012, 136(3):386-392.
155. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20(3):127-150. [Jun].
156. Maes M., Mihaylova I., Kubera M., Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012, 36(1):169-175.
157. Maj M., Pirozzi R., Formicola A.M., Bartoli L., Bucci P. Reliability and validity of the DSM-IV diagnostic category of schizoaffective disorder: preliminary data. J Affect Disord 2000, 57(1-3):95-98.
158. Maldonado M.D., Pérez-San-Gregorio M.A., Reiter R.J. The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CNS Drug Discov 2009, 4(1):61-69.
159. Mandal M., Marzouk A.C., Donnelly R., Ponzio N.M. Preferential development of Th17 cells in offspring of immunostimulated pregnant mice. J Reprod Immunol 2010, 87(1-2):97-100.
160. Margutti P., Delunardo F., Ortona E. Autoantibodies associated with psychiatric disorders. Curr Neurovasc Res 2006, 3(2):149-157.
161. Martín M., Macías M., León J., Escames G., Khaldy H., Acuña-Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002, 34(4):348-357.
162. Maserejian N.N., Hall S.A., McKinlay J.B. Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey. J Affect Disord 2012, 136(3):781-788.
163. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995, 152:1291-1297.
164. Mehendale S., Kilari A., Dangat K., Taralekar V., Mahadik S., Joshi S. Fatty acids, antioxidants, and oxidative stress in pre-eclampsia. Int J Gynaecol Obstet 2008, 100(3):234-238.
165. Meijer K., de Vries M., Al-Lahham S., Bruinenberg M., Weening D., Dijkstra M., et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One 2011, 6(3):e17154.
166. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:20-34. (this issue).
167. Meyer U., Nyffeler M., Schwendener S., Knuesel I., Yee B.K., Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 2008, 33:441-456.
168. Michel T.M., Sheldrick A.J., Camara S., Grünblatt E., Schneider F., Riederer P. Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. World J Biol Psychiatry 2011, 12(8):588-597.
169. Mika J., Rojewska E., Makuch W., Przewlocka B. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain. Neuroscience 2010, 165(4):1420-1428.
170. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006, 1073-1074:25-37.
171. Miller C.L., Murakami P., Ruczinski I., Ross R.G., Sinkus M., Sullivan B., et al. Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res 2009, 113(2-3):259-267.
172. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
173. Miyaoka T., Wake R., Furuya M., Liaury K., Ieda M., Kawakami K., et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37(2):222-226. [Jun 1].
174. Molina-Hernández M., Tellez-Alcántara N.P., Pérez-García J., Olivera-Lopez J.I., Jaramillo-Jaimes M.T. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(2):380-386.
175. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63:257-265.
176. Monji A., Takahiro A., Kato T.A., Mizoguchi Y., Horikawa H., Seki Y., et al. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:115-121. (this issue).
177. Monteleone P., Natale M., La Rocca A., Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 1997, 36(4):159-163.
178. Mork A., Geisler A. Effects of minocycline on accumulation of cyclic AMP in cerebral cortex of rat. A comparison with lithium. Neuropharmacology 1993, 32(8):793-798.
179. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry in press.
180. Müller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007, 12(11):988-1000.
181. Myint A.M., Leonard B.E., Steinbusch H.W., Kim Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005, 88(2):167-173.
182. Myint A.M., Schwarz M.J., Verkerk R., Mueller H.H., Zach J., Scharpé S., et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. Brain Behav Immun 2011, 25(8):1576-1581.
183. Nagels A., Kirner-Veselinovic A., Wiese R., Paulus F.M., Kircher T., Krach S. Effects of ketamine-induced psychopathological symptoms on continuous overt rhyme fluency. Eur Arch Psychiatry Clin Neurosci 2012, 262(5):403-414. [Aug].
184. Niimi S., Nakamura T., Nawa K., Ichihara A. Hormonal regulation of translatable RNA of tryptophan 2,3-dioxygenase in primary cultures of adult rat hepatocytes. J Biochem 1983, 94:1697-1706.
185. Nunes S.O., Vargas H.O., Brum J., Prado E., Vargas M.M., de Castro M.R., et al. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob Res 2012, 14(5):540-546. [May].
186. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008, 40:1053-1055.
187. Ohira K., Hagihara H., Toyama K., Takao K., Kanai M., Funakoshi H., et al. Expression of tryptophan 2,3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain 2010, 3:26.
188. Ohmori H., Kanayama N. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun Rev 2005, 4(4):224-229.
189. Owen A.J., Batterham M.J., Probst Y.C., Grenyer B.F., Tapsell L.C. Low plasma vitamin E levels in major depression: diet or disease?. Eur J Clin Nutr 2005, 59(2):304-306.
190. Ozbey U., Tug E., Kara M., Namli M. The value of interleukin-12B (p40) gene promoter polymorphism in patients with schizophrenia in a region of East Turkey. Psychiatry Clin Neurosci 2008, 62(3):307-312.
191. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19(2):89-95.
192. Ozcan O., Ipçioǧlu O.M., Gültepe M., Başoǧglu C. Altered red cell membrane compositions related to functional vitamin B(12) deficiency manifested by elevated urine methylmalonic acid concentrations in patients with schizophrenia. Ann Clin Biochem 2008, 45(Pt 1):44-49. [Jan].
193. Padurariu M., Ciobica A., Dobrin I., Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010, 479(3):317-320.
194. Pang D., Syed S., Fine P., Jones P.B. No association between prenatal viral infection and depression in later life-a long-term cohort study of 6152 subjects. Can J Psychiatry 2009, 54(8):565-570.
195. Park H.J., Park J.K., Kim S.K., Cho A.R., Kim J.W., Yim S.V., et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 2011, 45(2):304-308.
196. Pasco J.A., Jacka F.N., Williams L.J., Evans-Cleverdon M., Brennan S.L., Kotowicz M.A., et al. Dietary selenium and major depression: a nested case-control study. Complement Ther Med 2012, 20(3):119-123.
197. Peters D.A. Maternal stress increases fetal brain and neonatal cerebral cortex 5-hydroxytryptamine synthesis in rats: a possible mechanism by which stress influences brain development. Pharmacol Biochem Behav 1990, 35:943-947.
198. Phillips L.J., McGorry P.D., Garner B., Thompson K.N., Pantelis C., Wood S.J., et al. Stress, the hippocampus and the hypothalamic pituitary adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 2006, 40:725-741.
199. Pinto V.L., Brunini T.M., Ferraz M.R., Okinga A., Mendes-Ribeiro A.C. Depression and cardiovascular disease: role of nitric oxid. Cardiovasc Hematol Agents Med Chem 2008, 6(2):142-149.
200. Pol O., Sasaki M., Jiménez N., Dawson V.L., Dawson T.M., Puig M.M. The involvement of nitric oxide in the enhanced expression of mu-opioid receptors during intestinal inflammation in mice. Br J Pharmacol 2005, 145(6):758-766.
201. Pontes G.N., Cardoso E.C., Carneiro-Sampaio M.M., Markus R.P. Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res 2007, 43:365-371.
202. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:80.
203. Prosser E.S., Csernansky J.G., Kaplan J., Thiemann S., Becker T.J., Hollister L.E. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 1987, 175(2):100-105.
204. Prossin A.R., Koch A.E., Campbell P.L., McInnis M.G., Zalcman S.S., Zubieta J.K. Association of plasma interleukin-18 levels with emotion regulation and μ-opioid neurotransmitter function in major depression and healthy volunteers. Biol Psychiatry 2011, 69(8):808-812.
205. Quednow B.B., Csomor P.A., Chmiel J., Beck T., Vollenweider F.X. Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. Int J Neuropsychopharmacol 2008, 11(5):655-669.
206. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
207. Read J., Perry B.D., Moskowitz A., Connolly J. The contribution of early traumatic events to schizophrenia in some patients: a traumagenic neurodevelopmental model. Psychiatry 2001, 64:319-345.
208. Reale M., Patruno A., De Lutiis M.A., Pesce M., Felaco M., Di Giannantonio M., et al. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011, 12:13.
209. Reif A., Herterich S., Strobel A., Ehlis A.C., Saur D., Jacob C.P., et al. A neuronal nitric oxide synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal cortex function. Mol Psychiatry 2006, 11:286-300.
210. Reif A., Schecklmann M., Eirich E., Jacob C.P., Jarczok T.A., Kittel-Schneider S., et al. A functional promoter polymorphism of neuronal nitric oxide synthase moderates prefrontal functioning in schizophrenia. Int J Neuropsychopharmacol 2011, 14:887-897.
211. Robb R.J. Interleukin 2 and its cell-surface receptor. Behring Inst Mitt 1985, 77:5667.
212. Robert L. Diagnostic and Statistical Manual of Mental Disorders 1987, Revised, American Psychiatric Association, Washington DC, USA. 3rd edition.
213. Romero E., Guaza C., Castellano B., Borrell J. Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia. Mol Psychiatry 2010, 15:372-383.
214. Ruzicka B.B., Akil H. The interleukin-1beta-mediated regulation of proenkephalin and opioid receptor messenger RNA in primary astrocyte-enriched cultures. Neuroscience 1997, 79(2):517-524.
215. Salihu H.M., De La Cruz C., Rahman S., August E.M. Does maternal obesity cause preeclampsia? A systematic review of the evidence. Minerva Ginecol 2012, 64(4):259-280.
216. Salvatore P., Baldessarini R.J., Tohen M., Khalsa H.M., Sanchez-Toledo J.P., Zarate C.A., et al. McLean-Harvard international first-episode project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry 2009, 70(4):458-466.
217. Samuelsson A.M., Jennische E., Hansson H.A., Holmäng A. Prenatal exposure to interleukin-6 results in inflammatory neurodegeneration in hippocampus with NMDA/GABA(A) dysregulation and impaired spatial learning. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1345-R1356.
218. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22(2):67-73.
219. Schwarz M.J., Müller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001, 56:483-486.
220. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011, 16(7):751-762.
221. Silva R., Mesquita A.R., Bessa J., Sousa J.C., Sotiropoulos I., Leão P., et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neuroscience 2008, 152(3):656-669.
222. Siris S.G. Akinesia and post-psychotic depression: a difficult differential diagnosis. J Clin Psychiatry 1987, 48:240-243.
223. Siris S.G. Depression in schizophrenia: perspectives in the era of "atypical" antipsychotic agents. Am J Psychiatry 2000, 157:1379-1389.
224. Sivonova M., Zitnanova I., Hlincikova L., Skodacek I., Trebaticka J., Durackova Z. Oxidative stress in university students during examinations. Stress 2004, 7(3):183-188.
225. Siwek M., Dudek D., Paul I.A., Sowa-KucD́cma M., Zieba A., Popik P., et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 2009, 118(1-3):187-195.
226. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., et al. Indicators of immune activation in major depression. Psychiatry Res 1996, 64(3):161-167.
227. Smith K.A. T-cell growth factor: a lymphocytotropic hormone. Proceeding of the 55th Nobel symposium on genetics of the immune responses 1982, Plenum. G. Moller (Ed.).
228. Smith R.S., Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995, 45:135-141.
229. Soares-Weiser K., Maayan N., McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011, (2):CD000209.
230. Song C., Halbreich U., Han C., Leonard B.E., Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009, 42(5):182-188.
231. Songur A., Sarsilmaz M., Sogut S., Ozyurt B., Ozyurt H., Zararsiz I., et al. Hypothalamic superoxide dismutase, xanthine oxidase, nitric oxide, and malondialdehyde in rats fed with fish omega-3 fatty acids. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28(4):693-698.
232. Soria V., Martínez-Amorós E., Escaramís G., Valero J., Pérez-Egea R., García C., et al. Differential association of circadian genes with mood disorders: CRY1 and NPAS2 are associated with unipolar major depression and CLOCK and VIP with bipolar disorder. Neuropsychopharmacology 2010, 35(6):1279-1289. [May].
233. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 2001, 158(2):140-145.
234. Steiner J., Walter M., Gos T., Guillemin G.J., Bernstein H.G., Sarnyai Z., et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J Neuroinflammation 2011, 8:94.
235. Steullet P., Neijt H.C., Cuenod M., Do K.Q. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia. Neuroscience 2006, 137:807-819.
236. Stolk P., Souverein P.C., Wilting I., Leufkens H.G., Klein D.F., Rapoport S.I., et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010, 82(1):9-14.
237. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006, 27(2):71-80.
238. Szewczyk B., Kubera M., Nowak G. The role of zinc in neurodegenerative and inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(3):693-701.
239. Talarowska M., Galecki P., Maes M., Gardner A., Chamielec M., Orzechowska A., et al. Malondialdehyde plasma concentration correlates with declarative and working memory in patients with recurrent depressive disorder. Mol Biol Rep 2012, 39(5):5359-5366.
240. Talarowska M., Galecki P., Maes M., Orzechowska A., Chamielec M., Bartosz G., et al. Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neurosci Lett 2012, 510(2):127-131.
241. Taneli F., Pirildar S., Akdeniz F., Uyanik B.S., Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 2004, 35(5):401-405.
242. Tuovinen S., Räikkönen K., Pesonen A.K., Lahti M., Heinonen K., Wahlbeck K., et al. Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: the Helsinki Birth Cohort Study. J Psychiatr Res 2012, 46(3):303-310.
243. Turkez H., Togar B. The genotoxic and oxidative damage potential of olanzapine in vitro. Toxicol Ind Health 2010, 26(9):583-588.
244. Turkington A., Mulholland C.C., Rushe T.M., Anderson R., McCaul R., Barrett S.L., et al. Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. Br J Psychiatry 2009, 195(3):242-248.
245. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R-[11C] PK11195 positron emission tomography study. Biol Psychiatry 2008, 64:820-822.
246. van de Veerdonk F.L., Netea M.G., Dinarello C.A., Joosten L.A.B. Inflammasome activation and IL-1b and IL-18 processing during infection. Trends Immunol 2011, 32(3):110-116.
247. Ventura J., Nuechterlein K.H., Subotnik K.L., Gutkind D., Gilbert E.A. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatr Res 2000, 97(2-3):129-135.
248. Volk D.W., Radchenkova P.V., Walker E.M., Sengupta E.J., Lewis D.A. Cortical opioid markers in schizophrenia and across postnatal development. Cereb Cortex 2012, 22(5):1215-1223. [May].
249. Vucetic Z., Kimmel J., Totoki K., Hollenbeck E., Reyes T.M. Maternal high-fat diet alters methylation and gene expression of dopamine and opioid-related genes. Endocrinology 2010, 151(10):4756-4764.
250. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 2010, 30:1270-1287.
251. Wachter H., Fuchs D., Hausen A., Reibnegger G., Weiss G., Werner E.R., et al. Neopterin: biochemistry, methods, and clinical application 1992, Walter de Gruyter, Berlin-New York.
252. Wadee A.A., Kuschke R.H., Kometz S., Berk M. Personality factors, stress and immunity. Stress Health 2001, 17(1):25-40.
253. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002, 5(4):375-388.
254. Wichers M.C., Maes M. The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004, 29(1):11-17.
255. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpé S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10(6):538-544.
256. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A., Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 2007, 62(2):207-214.
257. Wood S.J., Yücel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann Acad Med Singapore 2009, 38(5):396-406. [May].
258. Wyatt R.J. Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 1991, 5:201-202.
259. Xie Y., Wang Y., Zhang T., Ren G., Yang Z. Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors. J Biomed Sci 2012, 19:14.
260. Yao J.K., Leonard S., Reddy R.D. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004, 30(4):923-934.
261. Yary T., Aazami S. Dietary intake of zinc was inversely associated with depression. Biol Trace Elem Res 2012, 145(3):286-290.
262. Yoon H.K., Kim Y.K., Lee H.J., Kwon D.Y., Kim L. Role of cytokines in atypical depression. Nord J Psychiatry 2012, 66(3):183-188. [Jun].
263. Zhang D., Wen X.S., Wang X.Y., Shi M., Zhao Y. Antidepressant effect of Shudihuang on mice exposed to unpredictable chronic mild stress. J Ethnopharmacol 2009, 123(1):55-60.